Bottom line
Is FRBRX a good fund? The bottom line
FRBRX is the Class R6 share class of Franklin Biotechnology Discovery Fund, a managed technology sector mutual fund from Franklin Templeton.
Its expense ratio is 0.67% — about $67 a year on every $10,000 invested, cheaper than 61% of technology sector funds we track.
It returned +52.8% over one year, +6.6% a year over five years, +7.4% a year over ten (as of Dec 31, 2025, per its prospectus).
With $1.2 billion in net assets and 126 holdings, its largest position is Jazz Pharmaceuticals plc (5.7%) and the top 10 make up 36.3% of the portfolio.
What stands out
- No front-end sales load
Updated Nov 19, 2026
What FRBRX invests in
Capital appreciation.
"Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The Fund predominantly invests in equity securities. For the Funds investment purposes, a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the companys most recent fiscal year. Discovery research firms are in the early stages of drug research. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such…
From the fund's prospectus (filed Aug 25, 2026).
FRBRX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FRBRX | +52.8% | +6.6% | +7.4% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2025
What FRBRX costs
On a $10,000 investment, FRBRX's 0.67% expense ratio costs about $67 a year. The prospectus estimates $955 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
FRBRX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Jazz Pharmaceuticals plc | 5.66% |
| 2 | Amgen, Inc. | 4.39% |
| 3 | Gilead Sciences, Inc. | 3.86% |
| 4 | Regeneron Pharmaceuticals, Inc. | 3.77% |
| 5 | Argenx SE | 3.62% |
| 6 | Vertex Pharmaceuticals, Inc. | 3.54% |
| 7 | Franklin Institutional U.S. Government Money Market Fund | 3.18% |
| 8 | Revolution Medicines, Inc. | 3.01% |
| 9 | Guardant Health, Inc. | 2.76% |
| 10 | Ascendis Pharma A/S | 2.56% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 36.3% of the fund. See all top 25 holdings and asset mix →